crossing96/oncoscreening huggingface dataset:
Tumor deposits in the impact of esophageal squamous cell carcinoma prognosis and recurrence: A multicenter retrospective cohort study.	PURPOSES: Tumor deposits (TDs) are considered poor prognostic factors in esophageal squamous cell carcinoma (ESCC). However, the impact of tumor deposits-positivity (TDP) on ESCC prognosis and recurrence remains unclear. This multicenter retrospective cohort study aimed to investigate the influence of TDP on recurrence and the potential benefit of adjuvant therapy in ESCC. METHODS: Data were collected from four large-scale hospitals on ESCC patients who underwent R0 esophagectomy for stage T1-4N0-3M0 from January 2008 to January 2019. The clinicopathological features, prognosis, and risk factors for TDP were evaluated. Subgroup analyses were conducted based on adjuvant chemotherapy status and recurrence patterns. RESULTS: A total of 2244 patients were enrolled in our study. 688 patients were analyzed after propensity score matching. Patients who were categorized as T1-4N0M0 with TDP status had a similar prognosis to T1-4N1M0 (P = 0.95) or T1-4N2M0 (P = 0.42) with tumor deposits-negativity (TDN) status. In the T1-4N0M0 and T1-4N1M0 stage groups, the 5-year RFS rate and 5-year OS in the TDP group differed significantly from the TDN group (P < 0.001). Among T1-4N0M0 with adjuvant chemotherapy patients, TDP patients had significantly worse OS compared to TDN patients (P < 0.001). Furthermore, TDP patients exhibited a higher cumulative incidence for local recurrence (P < 0.001) and distant recurrence rate (P < 0.001). CONCLUSIONS: TDP is a risk factor for recurrence in ESCC and plays a significant role in the discussion of ESCC treatment strategies. TDP patients may benefit from adjuvant chemotherapy, emphasizing the importance of monitoring these patients during follow-up.	esophagus
Information quality of videos related to esophageal cancer on tiktok, kwai, and bilibili: a cross-sectional study.	"BACKGROUND: Esophageal cancer typically lacks specific early symptoms, leading to late-stage diagnosis and poor prognosis, with an overall low 5-year survival rate. However, early detection and timely intervention can significantly improve the 5-year survival rate, underscoring the importance of prevention, screening, and early intervention. Short video platforms are increasingly utilized for health communication, offering opportunities to disseminate medical knowledge. However, the quality and reliability of health-related content, particularly for diseases like esophageal cancer, remain under explored. OBJECTIVE: This study aimed to systematically evaluate the quality, reliability, completeness, and engagement of esophageal cancer-related videos on three popular short video platform: Bilibili, TikTok, and Kwai, to identify platform-specific strengths and limitations in disseminating health information. METHODS: A total of 311 esophageal cancer-related videos were analyzed. Video assessment was assessed using 4 standardized scoring framework including General Quality Scores (GQS) for general quality, the DISCERN for reliability, Completeness Score (CS) for comprehensive information, Engagement Score (ES) for understandability and entertainment value of the video. Video features (source, category, content), user's behavior (likes, shares, comments) were also collected. Cross-platform comparisons were conducted to identify disparities in content quality and user interaction. RESULTS: This study analyzed 311 esophageal cancer-related videos on Bilibili, TikTok, and Kwai. Video quality varied significantly across platforms, with Bilibili showing the highest DISCERN (5.46), GQS (2.97) and CS (3.64), while TikTok videos achieved the highest ES (2.88) and engagement metrics (e.g., likes and collections, p < 0.001). Kwai videos had the lowest scores across all measures. Content focused primarily on ""symptoms"" and ""treatment,"" with Bilibili offering more comprehensive coverage. Correlation analysis revealed a positive association between video quality and engagement on Bilibili but a negative association on TikTok (e.g., GQS and likes, r=-0.251, P = 0.009). CONCLUSIONS: The quality of esophageal cancer-related videos across Bilibili, TikTok, and Kwai is suboptimal, with notable quality disparities among the platforms. Users on platforms other than Bilibili show limited ability to identify or prefer higher-quality content. This study underscores the potential of short-video platforms for esophageal cancer public health education, but highlights the need for improvements in content quality, ethical standards, and platform governance to address health equity concerns."	esophagus
Roles of MARCKSL1, MCM6, RFC4, and PLAU genes in esophageal cancer and their association with radiotherapy response.	Esophageal cancer is a highly lethal malignancy with high incidence and mortality rates, which continue to pose a significant threat to public health worldwide. Despite the adoption of multidisciplinary treatments, improving long-term survival rates remains a major challenge. Therefore, conducting in-depth research into the molecular mechanisms of esophageal cancer, identifying predictive biomarkers, and developing personalized treatment and monitoring strategies are crucial to enhancing clinical outcomes and patient prognosis. This study utilized advanced bioinformatics techniques to construct a gene co-expression network for esophageal cancer and compared it with sequencing data from real-world esophageal cancer samples. This approach successfully identified four key genes closely associated with the progression of esophageal cancer: MARCKSL1, MCM6, RFC4, and PLAU. A risk assessment model based on these genes demonstrated high predictive accuracy, particularly in assessing the risk of early-stage esophageal cancer, highlighting its significant potential for clinical application. Functional validation experiments and clinical data analysis further revealed that these genes play critical roles in esophageal cancer cell metastasis, glycolysis, and response to radiation therapy. These findings provide a new molecular basis for radiotherapy prognosis, helping to formulate more precise radiotherapy protocols and optimize treatment outcomes. Additionally, the regulatory networks of these genes revealed a complex molecular regulatory mechanism, offering new perspectives for precision treatment in esophageal cancer. In summary, these genes not only offer new insights into the early diagnosis and personalized treatment of esophageal cancer but also improve patient prognosis by correlating with radiotherapy response, thus laying a solid scientific foundation for future advancements.	esophagus
AKR1C3 enhances radioresistance in esophageal adenocarcinoma via inhibiting ferroptosis through suppressing TRIM21-mediated ubiquitination of HSPA5.	Esophageal adenocarcinoma (EAC) is the predominant subtype of esophageal cancer (EC) in high-income countries, and radioresistance is one of the key factors for the poor prognosis. In this study, we successfully established a radioresistant EAC in vitro model. Aldo-keto reductase 1C3 (AKR1C3) was identified as a promising regulator of radioresistance by RNA-seq analysis and subsequent functional studies. Through integrated analyses of scRNA-seq and TCGA datasets, we found that AKR1C3 was likely to enhance radioresistance by inhibition of ferroptosis. Indeed, analysis of the lipid ROS level by C11-Bodipy staining and the result of transmission electron microscopy revealed that AKR1C3 could prevent EAC cells from ferroptosis. Mechanistically, AKR1C3 binds to the nucleotide-binding domain of HSPA5, thereby inhibiting the E3 ligase TRIM21-induced ubiquitin-dependent proteasomal degradation of HSPA5, which further stabilizes GPX4, thus inhibiting ferroptosis. Importantly, AKR1C3 inhibitor resensitized the EAC patient-derived organoids to radiotherapy. In conclusion, this study highlights AKR1C3 as a regulator of radioresistance and a potential therapeutic target in EAC.	esophagus
Investigating the molecular mechanisms, drug prediction, and validation of CCNA2 and MAD2L1 in esophageal squamous cell carcinoma based on bioinformatics.	OBJECTIVE: Aims to comprehensively investigate the expression patterns of CCNA2 and MAD2L1 in esophageal squamous cell carcinoma using bioinformatics methods. METHODS: Based on WGCNA analysis of gene mutation expression, methylation level distribution, mRNA expression and ESCC-related genes in public databases, were employed for investigating potential biomarkers for prognosis of esophageal squamous cell carcinoma(ESCC).Finally,. performing qRT-PCR and immunohistochemistry to validate. RESULTS: Ultimately identified 4 hub genes: CDK1, CCNA2,TOP2A and MAD2L1. Bioinformatics analysis showed high expression of these four genes in ESCC (P < 0.05). CCNA2 and MAD2L1 were selected for subsequent analysis based on literature.3.Single gene enrichment analysis revealed significant enrichment of CCNA2 and MAD2L1 in pathways related to splicing, bladder cancer, non-homologous end joining and homologous recombination, glycosaminoglycan biosynthesis chondroitin sulfate, progesterone-mediated oocyte maturation and mismatch repair. PASTAA database indicated the involvement of transcription factors such as Roralpha1, Pou6f1, Roralpha2, Atf-1, Pax-3, C/ebpalpha, Nkx2-1 in the regulation of CCNA2, while no transcription factors were predicted for MAD2L1..Immune infiltration analysis revealed a close association between ESCC and plasma cells, CD8 + T cells, monocytes, M0 macrophages, M1 macrophages, dendritic cells, and resting mast cells.Drug prediction for CCNA2 included 7 drugs such as ETHINYL ESTRADIOL, Seliciclib and TAMOXIFEN, while no drugs were predicted for MAD2L1.qRT-PCR and immunohistochemistry demonstrated high expression of CCNA2 in ESCC, while MAD2L1 showed no significant difference between ESCC and normal esophageal squamous epithelial tissues. CONCLUSION: CCNA2 and MAD2L1 may be potential biomarkers for ESCC, providing a novel basis for understanding the molecular mechanisms underlying ESCC pathogenesis.Additionally, the potential drugs predicted for CCNA2 may emerge as a new hope for ESCC patients in the future.	esophagus
Evaluating the efficacy of adjuvant chemotherapy in cT1b-T2 patients with incidentally discovered positive lymph nodes after esophagectomy for esophageal squamous cell carcinoma: a retrospective cohort study.	BACKGROUND: This study evaluated the association between adjuvant chemotherapy and the survival of cT1b-T2 patients with incidentally discovered positive lymph nodes (cN- but pN+) after esophagectomy for esophageal squamous cell carcinoma. MATERIALS AND METHODS: Esophageal cancer patients in whom positive lymph nodes were incidentally discovered after esophagectomy were enrolled in this retrospective cohort study. Patients were divided into the surgery alone and adjuvant chemotherapy groups. Propensity score matching (1:1) was used to minimize baseline differences. RESULTS: In total, data from 343 patients who were incidentally discovered to have positive lymph nodes after surgery were analyzed. Each group consisted of 107 patients, with no significant difference in the background information between the two groups. There was also no significant difference in the overall survival (P = 0.227) or disease-free survival (P = 0.210) between the groups in the matched overall study population. Notably, in subgroup analysis, The disease-free survival in the adjuvant chemotherapy group was significantly better than that in the operation group alone for patients with pathological stage T3 (P = 0.023). Multivariate analysis showed that male (ref: female, HR = 1.796, 95% CI, 1.013-3.183, P = 0.045) was a significant independent predictive factor for overall survival. CONCLUSION: Adjuvant chemotherapy may improve survival for patients with cT1b-T2 but pathological T3 stage patients with incidentally discovered node-positive esophageal squamous cell carcinoma.	esophagus
"""You're just in such crisis mode…frantic to get through the next day"": an interpretative phenomenological analysis of adjustment experiences among carers of patients with advanced oesophago-gastric cancer."	BACKGROUND: In advanced oesophago-gastric cancer, rapid disease progression and complex symptoms contribute to a distinct caring context. Yet little is known about how those providing informal care interpret and adjust to these experiences, despite increasing recognition that this plays a key role in shaping psychological well-being. This study aimed to comprehensively explore these carers' adjustment experiences, identifying opportunities for improved care and support. METHODS: Semi-structured interviews were conducted with ten purposefully recruited individuals who had cared for someone with advanced oesophago-gastric cancer in the UK. The interviews were audio-recorded, transcribed verbatim, and analysed using interpretative phenomenological analysis. RESULTS: Carers experienced a demanding adjustment process as they took on complex nutritional and emotional responsibilities, often with limited guidance or support. The rapid trajectory and disruption to roles and routines left many feeling overwhelmed and unable to meet their own needs. Ongoing efforts to seek understanding, preserve connection, and focus on the present supported their attempts to manage uncertainty and sustain meaning. CONCLUSIONS: The findings reflect the unique complexities of advanced oesophago-gastric cancer care, pointing to the need for support models that acknowledge the complex, relational, and often hidden aspects of adjustment to caring in this context.	esophagus
Gender, racial, and socioeconomic disparities in the management and survival of patients with locally advanced esophageal cancer: a SEER-based study.	BACKGROUND: Esophageal cancer is the sixth most common gastrointestinal cancer in the United States. Treatment for esophageal cancer depends on the extent of the disease but often includes surgery with or without chemoradiation. The aim of this study is to identify possible gender, racial, and socioeconomic disparities in treatment decisions and survival outcomes for patients with locally advanced esophageal cancer. METHODS: Locally advanced (stage IIA-IVA) esophageal cancer cases in adults (age ≥ 20 years) diagnosed between 2012 and 2021 were identified from the Surveillance, Epidemiology, and End Results database. Data regarding patient demographics, treatment strategies, and survival outcomes was collected. Multivariate logistic and Cox regression analyses were performed to evaluate the association between various patient characteristics and management patterns and survival. RESULTS: A total of 10,823 cases were included in this study. Female (OR: 0.71, p < 0.001), Black (OR 0.33, p < 0.001), and Hispanic (OR: 0.75, p < 0.001) patients were less likely to be recommended surgery for their esophageal cancer. Among patients who were recommended surgery, Black race (OR: 0.062, p = 0.006) and Low SES (OR: 0.662, p = 0.007) were associated with a lower likelihood of surgery being performed. Female (OR: 0.74, p = 0.007) and Hispanic (OR 0.64, p = 0.003) patients were less likely to receive neoadjuvant therapy. Female (OR: 0.82, p = 0.040), Black (OR: 0.63, p = 0.018), and Low SES (OR: 0.734, p = 0.008) patients were less likely to receive adjuvant therapy. Female patients had improved OS (HR: 0.88, p < 0.001) and CSS (HR: 0.85, p = 0.003) whereas Black race (OS-HR: 1.32, p < 0.001, CSS-HR: 1.31, p < 0.001) and Low SES (OS-HR: 1.15, p < 0.001, CSS-HR: 1.17, p < 0.001) were associated with worse OS and CSS. CONCLUSIONS: Significant differences in surgical management, administration of neoadjuvant and adjuvant therapy, OS, and CSS exist based on gender, race/ethnicity, and SES. Further research is needed to elucidate and ameliorate the possible causes of these disparities.	esophagus
The distribution characteristics of PD-1 pathway-related immune cells in esophageal cancer tissue and their prognostic significance.	OBJECTIVE: This study aims to elucidate the distribution patterns of immune cells associated with the programmed cell death protein 1 (PD-1) pathway within esophageal cancer (EC) tissues and to determine their correlation with patient prognosis. METHODS: We included tissue samples from 236 EC patients who had undergone surgery at our institution between January 2016 and January 2021. This study examined the correlation between six immunohistochemical markers and the clinical profiles of these patients. Survival analysis was performed using the Kaplan-Meier method and the LOG-rank test to evaluate the impact of immunohistochemical marker expression on patient survival. A clinical predictive model was developed and validated for prognostic assessment. RESULTS: Expression levels of PD-1, PD-L1, FOXP3, and CD25 were found to be positively associated with the depth of tumor invasion and lymph node metastasis (P < 0.05). In contrast, CD4 and CD8 expression levels were inversely related to these parameters (P < 0.05). High expression of PD-1, PD-L1, FOXP3, and CD25, along with lymph node metastasis, were identified as independent prognostic risk factors (P < 0.05). Patients with low expression of PD-1, PD-L1, FOXP3, CD25, and high expression of CD4 and CD8 exhibited improved three-year survival rates (P < 0.001). The predictive model, based on these factors, demonstrated high discrimination and accuracy. CONCLUSION: A prognostic model incorporating the expression levels of PD-1, PD-L1, FOXP3, CD25, and lymphocyte infiltration offers robust predictive validity for the prognosis of EC patients.	esophagus
Investigation of the diagnostic and prognostic impact of posttreatment fluorine-18 fluorodeoxyglucose PET/computed tomography on M0 esophageal cancer.	OBJECTIVE: Fluorine-18 fluorodeoxyglucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) is an essential examination to stage patients with esophageal cancer; however, the role of posttreatment [18F]FDG PET/CT in patients with esophageal cancer has not been well explored. We aimed to investigate the prognostic and diagnostic value of posttreatment PET/CT in patients with esophageal cancer after their definitive treatment. METHODS: This retrospective study enrolled 208 patients with biopsy-proven esophageal cancer. Posttreatment PET/CT scans were performed greater than or equal to 3 months after the completion of definitive therapy, with a total of 539 scans included in this study. The outcome measures were the diagnostic capacity of PET/CT and patient survival. Survival analysis was conducted using Kaplan-Meier plots, accompanied by the Mantel-Cox log-rank test and Cox regression. RESULTS: The sensitivity, specificity, and accuracy of posttreatment PET/CT for recurrent tumors were 93.67, 92.65, and 92.95%, respectively. PET/CT identified recurrent tumors in 24.58% of scans obtained for tumor surveillance and ruled out recurrence in 40.30% of scans obtained with prior clinical suspicion. Negative PET/CT had a predictive value of 80% for nonrecurrence before the next planned scan, while positive PET results were significantly associated with poorer patient survival following the scan ( P < 0.0001). In the multivariate Cox regression model, the PET/CT result was identified as an independent prognostic factor [ P < 0.0001, hazard ratio (HR)=3.818] with a higher hazard ratio compared with the tumor stage ( P = 0.01, HR=1.633) or treatment modality ( P = 0.0002, HR = 2.035). CONCLUSION: We illustrate the favorable performance of posttreatment [18F]FDG PET/CT in both detecting tumor recurrence and evaluating the prognosis of patients with M0 esophageal cancer. These findings imply the potential of [18F]FDG PET/CT as a follow-up imaging modality in these patients.	esophagus
Lymphocyte nadir and recovery dynamics for locally advanced thoracic malignancies undergoing concurrent chemo-irradiation: Establishment of organs-at-risk constraints.	BACKGROUND AND PURPOSE: Radiotherapy-induced-lymphopenia (RIL) worsens outcome in thoracic malignancies on radiotherapy (RT). We hypothesised that post-RT absolute lymphocyte count (ALC) nadir and recovery were independently prognostic for overall survival (OS) and progression-free survival (PFS) in thoracic malignancies following radical chemo-irradiation. We also aimed to determine relevant organs-at-risk (OARs) constraints. METHODS AND MATERIALS: Two independent cohorts of stage III non-small-cell lung cancer (NSCLC) and stage II to III oesophageal cancer (EC) patients receiving chemo-irradiation from 2013 to 2022 were analysed. ALC nadir was defined as the lowest ALC on RT. ALC recovery index (ARI) was the ALC at 6 months/Pre-RT ALC. Effect of ALC nadir and ARI on OS and PFS were evaluated. RT dose of OARs was correlated with ALC nadir and ARI. OAR thresholds were then determined. RESULTS: High ARI and ALC nadir were independently prognostic of improved OS and PFS for both cohorts. In NSCLC, thoracic spine V35Gy and ribs V35Gy were associated with ARI. Cut-off for thoracic spine V35Gy was 25.5 % while ribs V35Gy cut-off was 6.6 %. Thoracic spine V20Gy and Mean lung dose (MLD) were associated with ALC nadir in NSCLC. MLD cut-off was 16.5 Gy while T spine V20Gy cut off was 25.6 %. For EC, thoracic spine V35Gy was also associated with ARI. Similar to NSCLC, cut-off was 25.7 %. MLD and spleen V5Gy were associated with ALC nadir. MLD and Spleen V5Gy cut-off was 10.6 Gy and 7.2 % respectively. CONCLUSION: Post-RT lymphocyte nadir and recovery were both important for survival outcomes. Future prospective studies are warranted to validate whether abiding to lymphocyte sparing OARs constraints developed in the current study can improve lymphopenia and outcomes.	esophagus
The Usefulness of the Modified Advanced Lung Cancer Inflammation Index (mALI) as a Prognostic Factor in Patients With Esophageal Cancer who Have Undergone Curative Resection.	BACKGROUND/AIM: In several previous studies, the modified advanced lung cancer inflammation index (mALI) has been reported to be a useful prognostic factor in non-small cell lung cancer. This study aimed to demonstrate the relationship between mALI and the oncological prognosis of patients with esophageal cancer (EC) who underwent curative treatment and to clarify the underlying mechanism. PATIENTS AND METHODS: We retrospectively followed up patients who underwent curative resection of esophageal cancer at Yokohama City University between 2000 and 2020 and extracted clinical data from their medical records. mALI was defined as follows: mALI=[L3 muscle index (L3MI) (cm(2)/m(2))×albumin (g/l)]/neutrophil-to-lymphocyte ratio (NLR) [neutrophil count÷lymphocyte count]. RESULTS: A total of 196 patients were selected for this study, and the cutoff value for mALI was set separately for male and females. When the cutoff value was set at 10 for males and 12 for females, 84 patients were assigned to the mALI-low group and 112 patients were assigned to the mALI-high group. A survival analysis revealed that the 5-year overall survival (OS) rate was 50.3% in the mALI-low group and 62.5% in the mALI-high group (p=0.014). A multivariate analysis of OS revealed that mALI was an independent prognostic factor. The 5-year recurrence-free survival (RFS) rates were 33.0% in the mALI-low group and 44.9% in the mALI-high group (p=0.044). The multivariate analysis of RFS revealed that mALI was an independent prognostic factor. In addition, the mALI-low group had a higher rate of hematogenous metastasis than the mALI-high group. CONCLUSION: mALI is associated with the oncological prognosis of patients with EC who have undergone radical resection via several mechanisms and is a useful prognostic factor.	esophagus